Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells
- PMID: 7477684
- DOI: 10.2176/nmc.35.423
Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells
Abstract
The secretion of transforming growth factor-beta (TGF-beta), a growth inhibitory factor with immunosuppressive properties, was investigated in one glioblastoma cell line and seven surgically resected malignant glioma cells. Cultured cells from surgically resected tumors were examined immunohistochemically for glial fibrillary acidic protein (GFAP) and S-100 protein. The levels of TGF-beta 1 and TGF-beta 2 in culture supernatants from malignant glioma cells were determined by a specific bioassay using anti-TGF-beta 1 and anti-TGF-beta 2 antibodies. Two glioblastoma cell lines were cultured in the presence of TGF-beta 1 or TGF-beta 2 to assess the effect of TGF-beta on the growth of glioblastoma cells. Cultured cells from surgically resected tumors were positive for both GFAP and S-100 protein. Both active and latent forms of TGF-beta 1 and TGF-beta 2 were detected in the culture supernatants from malignant gliomas, except in one patient with anaplastic astrocytoma which secreted only latent forms of TGF-beta 1 and TGF-beta 2. There was no statistical difference in the levels of TGF-beta 1 and TGF-beta 2 in glioblastomas and anaplastic astrocytomas. Neither TGF-beta 1 nor TGF-beta 2 affected the growth of glioblastoma cells. These findings suggest that most malignant glioma cells secrete both TGF-beta 1 and TGF-beta 2, can convert TGF-beta from a latent to active form, and may suppress cytokine secretion by activated lymphocytes in vivo as well as in vitro.
Similar articles
-
Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.Neuropathology. 2000 Sep;20(3):161-9. doi: 10.1046/j.1440-1789.2000.00327.x. Neuropathology. 2000. PMID: 11132930
-
Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.J Neurooncol. 1997 Jul;33(3):195-200. doi: 10.1023/a:1005791621265. J Neurooncol. 1997. PMID: 9195490
-
Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells.Neurol Med Chir (Tokyo). 1996 Nov;36(11):789-95. doi: 10.2176/nmc.36.789. Neurol Med Chir (Tokyo). 1996. PMID: 9420430
-
Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection?Ciba Found Symp. 1991;157:232-8; discussion 238-41. doi: 10.1002/9780470514061.ch15. Ciba Found Symp. 1991. PMID: 1649035 Review.
-
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.Brain Res Brain Res Rev. 1995 Sep;21(2):128-51. doi: 10.1016/0165-0173(95)00010-0. Brain Res Brain Res Rev. 1995. PMID: 8866671 Review.
Cited by
-
Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models.Front Oncol. 2020 Aug 18;10:1117. doi: 10.3389/fonc.2020.01117. eCollection 2020. Front Oncol. 2020. PMID: 32974124 Free PMC article.
-
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.Neuro Oncol. 2007 Jul;9(3):259-70. doi: 10.1215/15228517-2007-010. Epub 2007 May 23. Neuro Oncol. 2007. PMID: 17522330 Free PMC article.
-
Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.J Neurooncol. 2006 Aug;79(1):61-5. doi: 10.1007/s11060-005-9116-7. Epub 2006 Apr 14. J Neurooncol. 2006. PMID: 16614941
-
Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment.Int J Mol Sci. 2018 Apr 8;19(4):1115. doi: 10.3390/ijms19041115. Int J Mol Sci. 2018. PMID: 29642503 Free PMC article. Review.
-
Immunotherapeutic approaches for glioma.Crit Rev Immunol. 2009;29(1):1-42. doi: 10.1615/critrevimmunol.v29.i1.10. Crit Rev Immunol. 2009. PMID: 19348609 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
